Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

13 Sep 2010 13:45

RNS Number : 5814S
Nomura Code Securities Limited
13 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

10 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.0

563,377

0.2

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

0.0

563,377

0.2

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord shares

Purchase

35,000

11.5 p

Total

Purchases:

35,000

Ord shares

Sale

428,449

11.67 p

Total

Sales:

428,449

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

13 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUOSURRSAKAAR
Date   Source Headline
11th Jul 20187:00 amRNSLicensee Quark Pharmaceuticals Patient Dosed Ph 3
21st Jun 20187:00 amRNSSilence Strengthens Board and Leadership Team
18th Jun 20184:35 pmRNSPrice Monitoring Extension
15th Jun 20187:00 amRNSPresents Data on Lead Programme SLN124 at EHA
4th Jun 201810:15 amRNSSilence Therapeutics Announces Leadership Change
24th Apr 20187:00 amRNSResults of AGM
19th Apr 20185:00 pmRNSAdditional Listing
3rd Apr 20187:00 amRNSLitigation Update (Portugal and US)
26th Mar 20187:00 amRNSSilence to Present at Scientific Conferences
7th Mar 20187:00 amRNSNotice of AGM
6th Mar 20187:00 amRNSPreliminary results year ended 31 December 2017
5th Mar 20187:00 amRNSSilence to present at Cowen Health Care Conference
22nd Feb 20183:40 pmRNSHolding(s) in Company
20th Feb 20187:00 amRNSNotice of Results
15th Feb 20182:27 pmRNSAdditional Listing
2nd Feb 201811:38 amRNSGrant of share options and restricted stock units
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 201811:48 amRNSHolding(s) in Company
22nd Jan 20187:00 amRNSKey European patent granted
8th Jan 20187:00 amRNSPost year end business update
28th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
15th Dec 20174:40 pmRNSSecond Price Monitoring Extn
15th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20174:35 pmRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
4th Dec 20177:00 amRNSPartial Disposal of Arrowhead common shares
20th Nov 20177:00 amRNSUpdate on litigation matters
14th Nov 20177:00 amRNSCapital Markets Day
3rd Nov 20177:00 amRNSUpdate on Litigation Matters
2nd Nov 20174:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20179:24 amRNSHolding(s) in Company
24th Oct 20173:59 pmRNSHolding(s) in Company
19th Oct 20175:50 pmRNSHolding(s) in Company
18th Oct 20172:31 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSFurther US patents granted
17th Oct 20173:08 pmRNSServing of claim in the UK High Court
16th Oct 20177:00 amRNSAppointment of Non-Executive Chair
11th Oct 20177:00 amRNSKey US patent granted
6th Oct 20172:40 pmRNSHolding(s) in Company
28th Sep 20171:10 pmRNSHolding(s) in Company
27th Sep 20172:39 pmRNSHolding(s) in Company
27th Sep 20179:48 amRNSHolding(s) in Company
26th Sep 201711:48 amRNSHolding(s) in Company
22nd Sep 20174:00 pmRNSHolding in Company
22nd Sep 20173:15 pmRNSHolding in Company
22nd Sep 20172:15 pmRNSHolding in Company
22nd Sep 20172:01 pmRNSHolding in Company
22nd Sep 20172:00 pmRNSHolding in Company
20th Sep 201712:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.